VIDA is a clinical intelligence company focused on enhancing the efficiency of respiratory clinical trials through advanced data-driven solutions. Their proprietary platform, known as Lung Intelligence, leverages digital biomarker technology to streamline the clinical trial process. By utilizing precision endpoints and optimized imaging operations, VIDA aims to reduce the high costs and inefficiencies associated with respiratory drug development, which often sees a significant failure rate in late-stage trials. The company emphasizes the importance of data insights in accelerating the approval and adoption of new therapies for lung disorders, which affect a substantial portion of the adult population.

In addition to its innovative trial solutions, VIDA has achieved regulatory clearances for its products, including VIDA Insights and VIDA Discovery, in both the US and Canada. The company adheres to strict compliance standards, including HIPAA regulations and ISO certification, ensuring that its operations meet the highest levels of data privacy and security. By integrating these technologies and compliance measures, VIDA is positioned to significantly impact the landscape of respiratory healthcare, ultimately aiming to bring effective therapies to patients more rapidly.

United States

VIDA is a clinical imaging intelligence company that is accelerating the approval and adoption of life-saving therapies to patients through an AI-powered digital biomarker solution. With proprietary imaging biomarkers for precise quantitative endpoints and a trial imaging management solution, VIDA's solution is helping biopharma sponsors save millions in drug development costs.

VIDA

Company Details